Breaking News

Allergan Acquires TARIS Biomedical’s Lead Program

August 14, 2014

LiRIS candidate in Phase II development for cystitis, bladder pain

Allergan has acquired worldwide rights to TARIS Biomedical’s lead program, LiRIS, currently in Phase II development for the treatment of interstitial cystitis / bladder pain syndrome (IC/BPS), for $67.5 million in cash. Allergan will also pay as much as $295 million in development milestones, and as much as $225 million in commercial milestones.
 
TARIS previously spun out certain assets, including pipeline programs and intellectual property related to TARIS’ platform technology, to a new company funded by TARIS shareholders.
 
“Allergan has a longstanding history of delivering stockholder value by developing innovative medical treatments that address unmet medical needs,” said David E.I. Pyott, chairman of the board and chief executive officer, Allergan. “The acquisition of LiRIS is an important addition to our growing urology pipeline and, if approved, will provide a local treatment for interstitial cystitis / bladder pain syndrome, which is a debilitating bladder condition.”
 
“This transaction is a win for patients, for our shareholders and employees, and for the future potential of our core delivery technologies,” said Purnanand Sarma, Ph.D., president and chief executive officer of TARIS. “Allergan is an ideal partner for advancing LiRIS because of its team’s expertise in drug delivery technologies, specialty product development and commercialization in the urology market. Building on the success of LiRIS so far, we will now be able to focus our efforts on developing a rich pipeline of applications of our technology, including new treatments for bladder cancer and other areas of unmet need in urology.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.